Estrogen With a Pessary: What Changed?

A prescription for vaginal estrogen alongside a pessary should come with an explanation of its purpose. Ask whether the aim is treating vaginal symptoms, reducing a particular complication or helping you continue using the device. Those goals need different measures of success.

The primary result

A Chinese trial randomized 420 postmenopausal women after successful fitting with a support ring pessary. It tested Nuziline conjugated-estrogen cream, 1 g (0.625 mg/g) nightly for two weeks, then twice weekly, against placebo.¹

At 12 months, continued use with satisfaction occurred in 181/208 versus 176/203: 87.0% versus 86.7%, a difference of 0.3 percentage points (95% CI −6.2 to 6.9). Satisfaction meant feeling much or very much better. Use meant at least five days weekly. Four women had no follow-up; five were found ineligible after randomization.¹

This does not establish equivalence.¹

Ask the fitter to write down what would count as a useful change for you. If the problem is discomfort while wearing the device, describe where it happens and whether it changes after removal. If dryness is also present without the pessary, say that separately.

Complications need a separate reading

Erosion or ulcer occurred in 4/208 versus 14/203. This secondary finding is tentative, not proof of improved continuation or rare-event safety. Public funding supported the trial; Nuziline supplied both creams.¹

Other pessary types were not tested.¹

In the UK’s NICE² guidance, vaginal estrogen is considered for menopause-associated genitourinary symptoms and signs before pessary treatment. It is not presented as mandatory for every user. NICE also advises discussing repeat fittings, sexual intercourse, discharge, bleeding, removal difficulties and expulsion.²

A review appointment should distinguish the device’s fit from the reason for prescribing a cream. Bring the exact product name and prescribed amount. Record when symptoms began, whether you removed the pessary, and whether they returned after reinsertion. These details give the clinician something more specific to assess than “the treatment isn’t working.”

Treatment still needs a care plan

The studied Chinese cream was not US Premarin. For US readers, the current Premarin vaginal-cream label covers vaginal atrophy conditions and menopause-related pain with sex, not pessary continuation. Its labeled schedules differ from this trial’s regimen; do not substitute one product’s instructions for another’s.³

Premarin’s label lists unexplained genital bleeding, breast cancer or its history, certain estrogen-dependent tumors, blood-clot or stroke history, liver disease and certain clotting disorders among contraindications. Systemic absorption occurs. Report bleeding after menopause promptly rather than assuming it is friction from a pessary.³

NICE² says a pessary should be removed at least every six months to prevent serious complications. People whose physical or cognitive impairments make care difficult should be offered six-monthly pessary-clinic appointments. This sets a minimum removal requirement, not an instruction to leave every device untouched for six months.²

Before leaving the appointment, confirm who removes and cleans your device, the schedule for your pessary, and whom to call between visits. If you cannot carry out the agreed routine, tell the service so it can arrange help.

Our pelvic organ prolapse overview explains the condition and treatment options. The prescription-options section in Down There, Decoded explains vaginal estrogen and other treatments for menopause-associated vaginal symptoms. Use it for that background; your pessary service should provide the device-care instructions.